Comparative Efficacy and Safety of Semaglutide, Cagrilintide, and CagriSema for the Treatment of Type 2 Diabetes Mellitus: A Bayesian Network Meta Analysis Journal of Clinical Question A new drug combo of semaglutide (GLP 1 receptor agonist) with cagrilintide (amylin analogue) failed to do as well as tirzepatide (GLP 1 GIP receptor agonist). The future of these medicines is hitting different receptors. CagriSema: The New GLP 1 and Amylin Combination That May Transform Obesity Treatment Larvol Delta CagriSema drives weight loss in rats by reducing energy intake and preserving energy expenditure Nature Metabolism Updates in Medicine REDEFINE 2: CagriSema in T2D + Obesity Original article link in bio Phase 3a RCT in 1206 adults with T2D (BMI 27, HbA1c 710%) Instagram